Recent CRVS News
- Corvus Pharmaceuticals to Provide Business Update and First Quarter 2024 Financial Results on May 6, 2024 • GlobeNewswire Inc. • 05/02/2024 08:02:00 PM
- Corvus Pharmaceuticals Announces Pricing of $30.6 Million Registered Direct Offering • GlobeNewswire Inc. • 05/02/2024 12:30:00 PM
- Corvus Pharmaceuticals Announces Initiation of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis • GlobeNewswire Inc. • 04/09/2024 08:01:00 PM
- Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results • GlobeNewswire Inc. • 03/19/2024 08:02:00 PM
- US Index Futures Decline Ahead of Federal Reserve Meeting, Oil Prices Retreat • IH Market News • 03/19/2024 11:27:29 AM
- Corvus Pharmaceuticals to Provide Business Update and Fourth Quarter and Full Year 2023 Financial Results on March 19, 2024 • GlobeNewswire Inc. • 03/13/2024 08:02:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/01/2024 10:57:04 PM
- Corvus Pharmaceuticals Presents Soquelitinib Preclinical Data at the Keystone Symposia on Systemic Autoimmune and Autoinflammatory Diseases • GlobeNewswire Inc. • 02/12/2024 01:30:00 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 02/08/2024 09:27:12 PM
- Corvus Pharmaceuticals Announces Orphan Drug Designation Granted to Soquelitinib for the Treatment of T Cell Lymphoma • GlobeNewswire Inc. • 02/08/2024 09:05:00 PM
- Corvus Pharmaceuticals Appoints Jeffrey Arcara as Chief Business Officer • GlobeNewswire Inc. • 02/06/2024 09:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/23/2024 10:00:15 PM
- Corvus Pharmaceuticals Announces the Passing of Board Member Edith P. Mitchell • GlobeNewswire Inc. • 01/23/2024 10:00:00 PM
- Corvus Pharmaceuticals Presents New Interim Soquelitinib Data from its Phase 1/1b T Cell Lymphoma Trial • GlobeNewswire Inc. • 12/09/2023 05:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/08/2023 09:07:24 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/08/2023 09:03:53 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/07/2023 09:03:02 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/07/2023 09:02:38 PM
- Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2023 Financial Results • GlobeNewswire Inc. • 11/07/2023 09:01:00 PM
- Corvus Pharmaceuticals to Present New Interim Soquelitinib Data from its Phase 1/1b T Cell Lymphoma Trial at the 65th American Society of Hematology (ASH) Annual Meeting & Exposition • GlobeNewswire Inc. • 11/02/2023 01:15:00 PM
- Corvus Pharmaceuticals Announces Publication of Preclinical Data Demonstrating Potential of ITK Inhibition with Soquelitinib as a Novel Approach to T Cell-Mediated Inflammatory and Immune Diseases • GlobeNewswire Inc. • 11/01/2023 11:31:53 PM
- Corvus Pharmaceuticals to Provide Business Update and Report Third Quarter Financial Results on November 7, 2023 • GlobeNewswire Inc. • 10/31/2023 08:02:00 PM
- Corvus Pharmaceuticals Confirms Planned Initiation of Soquelitinib (CPI-818) Phase 3 Registrational Clinical Trial in Peripheral T Cell Lymphoma Following Meeting with FDA • GlobeNewswire Inc. • 09/06/2023 08:05:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/08/2023 08:02:33 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/08/2023 08:01:11 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM